Ipsen Appoints Olivia Brown as EVP, Global Head of Neurotoxins

Ipsen (Euronext: IPN; ADR: IPSEY) has announced the appointment of Olivia Brown as Executive Vice President, Global Head of Neurotoxins, effective April 1, 2025. In this newly created role, Brown will lead Ipsen’s global neurotoxins franchise, overseeing strategy and execution across therapeutic and aesthetic applications. She will report directly to Ipsen CEO David Loew and serve on the company’s Executive Leadership Team.With over 20 years of experience in pharmaceuticals and medical aesthetics, Brown has led business transformation, market expansion, and product launches at companies such as Novartis, Merz Aesthetics, and Galderma. Her expertise aligns with Ipsen’s ambitions in neurotoxin innovation, particularly with its Long-Acting Neurotoxin (LANT) program, designed to enhance treatment efficacy and durability.“Ipsen has a strong foundation in innovation, and I look forward to working with the team to drive further growth in this dynamic market,” said Brown.This strategic appointment underscores Ipsen’s commitment to advancing neurotoxin therapies and strengthening its position in both therapeutic and aesthetic markets.